1. Sgouros, G., Ballangrud, A.M., Jurcic, J.G., et al., J. Nucl. Med., 1999, vol. 40, no. 11, pp. 1935–1946.
2. Chemotherapy and Monoclonal Antibody Therapy in Treating Patients with Advanced Myeloid Cancer, http://www.clinicaltrials.gov/ct2/show/NCT00014495 .
3. Protein Design Labs Licenses Development Rights to SMART M195 Antibody to Actinium Pharmaceuticals, Actinium Pharmaceuticals Inc. Press Release from March 18, 2003.
4. Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients with Advanced Myeloid Malignancies, http://www.clinicaltrials.gov/ct2/show/study/NCT00672165 .
5. Nilsson, S., Larsen, R.H., Fossa, S., et al., Clin. Cancer Res., 2005, vol. 11, no. 12, pp. 4451–4459.